Position in REPL
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$538,254
New position
Shares Held
70,360
first reported quarter
Ownership
0.084%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026ZACKS INVESTMENT MANAGEMENT holds $41,029,792 across 10 Biotechnology names. REPL ranks #9 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
55,082 | $24,596,316 | |
| 2 | KRYS |
Krystal Biotech, Inc.
|
17,919 | $4,628,835 | |
| 3 | MIRM |
Mirum Pharmaceuticals, Inc.
|
36,889 | $3,407,804 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
7,857 | $2,599,644 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
30,852 | $1,993,963 | |
| 6 | ADMA |
Adma Biologics, Inc.
|
118,702 | $1,069,505 | |
| 7 | TARS |
Tarsus Pharmaceuticals, Inc.
|
14,879 | $1,043,761 | |
| 8 | ARVN |
Arvinas, Inc.
|
66,978 | $709,966 |
All Filings in REPL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $538,254 | 70,360 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||